Inhibition of bacterial carbonic anhydrases and zinc proteases: From orphan targets to innovative new antibiotic drugs

Current Medicinal Chemistry

Volumn 19, Issue 6, 2012, Pages 831-844

  Supuran, C T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anthrax lethal factor; Antibacterial agent; Botulinum neurotoxin; Carbonic anhydrase; Clostridium histolyticum collagenase; Enzyme inhibitor; Protease; Tetanus neurotoxin; Zinc protease

Indexed keywords

ANION; ANTHRAX TOXIN; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BOTULINUM TOXIN; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE ALPHA; CARBONATE DEHYDRATASE BETA; CARBONATE DEHYDRATASE GAMMA; COLLAGENASE; METALLOPROTEINASE; SULFONAMIDE; TETANUS TOXIN; UNCLASSIFIED DRUG; ZINC METALLOPROTEINASE;

BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BRUCELLA; CATALYSIS; CLOSTRIDIUM; CLOSTRIDIUM HISTOLYTICUM; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG TARGETING; ENTEROCOCCUS; ENZYME PURIFICATION; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; LEGIONELLA PNEUMOPHILA; LIFE CYCLE; LISTERIA; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA ENTERICA; STREPTOCOCCUS PNEUMONIAE; STREPTOMYCES; VIBRIO; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; HUMANS; METALLOENDOPEPTIDASES; PROTEASE INHIBITORS; ZINC;

EID: 84857540928     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799034824     Document Type: Review

References (129)

1. Supuran, C.T.; Winum, J.Y. (Eds). Drug Design of Zinc Enzyme Inhibitors -Functional, Structural and Diseses Applications, Wiley, 2009, pp. 1-1022, and references cited in it.
2. Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discovery 2008, 7, 168-181 (Pubitemid 351194064)
3. Supuran, C.T. Carbonic anhydrase inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 3467-3474.
4. Supuran, C.T.; Scozzafava, A.; Clare, B.W. Bacterial protease inhibitors. Med. Res. Rev. 2002, 22, 329-372. (Pubitemid 34620472)
5. Travis, J.; Potempa, J. Bacterial proteinases as targets for the development of second generation antibiotics. Biochim Biophys Acta 2000, 1477, 35-50. (Pubitemid 30119890)
6. Supuran, C.T. Carbonic anhydrase inhibition/activation: Trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr. Pharm. Des. 2010, 16, 3233-3245.
7. Supuran, C.T. Bacterial carbonic anhydrases as drug targets: Towards novel antibiotics. Front. Pharmacol. 2011, 2, 34.
8. Maeda, H. Role of microbial proteases in pathogenesis. Microbiol. Immunol. 1996, 40, 685-699. (Pubitemid 26376146)
9. Rice, S.A.; Givskov, M.; Steinberg, P.; Kjelleberg, S. Bacterial signals and antagonists: The interaction between bacteria and higher organisms. J. Mol. Microbiol. Biotechnol. 1999, 1, 23-31. (Pubitemid 129491921)
10. Watanabe, K. Other bacterial zinc peptidases as potential drug targets. In Drug Design of Zinc Enzyme Inhibitors -Functional, Structural and Diseses Applications, Supuran, C.T.; Winum, J.Y. (Eds). Wiley, 2009, pp. 731-748.
11. Mastrolorenzo, A.; Rusconi, S.; Scozzafava, A.; Barbaro, G.; Supuran, C.T. Inhibitors of HIV-1 protease: Current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr. Med. Chem. 2007, 14, 2734-2748. (Pubitemid 350130917)
12. Barbaro, G.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C.T. Highly active antiretroviral therapy: Current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 2005, 11, 1805-1843. (Pubitemid 40668138)
13. Furtado, G.H.; Nicolau, D.P. Overview perspective of bacterial resistance. Expert Opin. Ther. Pat. 2010, 20, 1273-1276.
14. Ginsberg, A.M. Emerging drugs for active tuberculosis. Semin. Respir. Crit. Care Med. 2008, 29, 552-559.
15. Dye, C. Doomsday postponed? Preventing and reversing epidemics of drugresistant tuberculosis. Nat Rev Microbiol. 2009, 7, 81-87.
16. Bush, K.; Macielag, M.J. New β-lactam antibiotics and β-lactamase inhibitors. Expert Opin. Ther. Pat. 2010, 20, 1277-1293.
17. Cloeckaert, A.; Schwarz, S. Molecular characterization, spread and evolution of multidrug resistance in Salmonella enterica typhimurium DT104. Vet. Res. 2001, 32, 301-310 (Pubitemid 32595213)
18. Nickerson, C.A; Schurr, M.J. Molecular paradigms of infectious disease: A bacterial perspective. Springer Verlag, Munich, 2006, pp. 1-617.
19. Payne, D.J.; Gwynn, M.N.; Holmes, D.J.; Pompliano, D.L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 2007, 6, 29-40. (Pubitemid 46020284)
20. Showalter, H.D.; Denny, W.A. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis (Edinb). 2008, 88 Suppl 1, S3-17.
21. Suerbaum, S.; Michetti, P. Helicobacter pylori infection. N. Engl. J. Med. 2002, 347, 1175-1186
22. Tsolis, R.M.; Young, G.M.; Solnick, J.V.; Bäumler, A.J. From bench to bedside: Stealth of enteroinvasive pathogens. Nat. Rev. Microbiol. 2008, 6, 883-892
23. Chiricǎ, L.C.; Elleby, B.; Jonsson, B.H.; Lindskog, S. The complete sequence, expression in Escherichia coli, purification and some properties of carbonic anhydrase from Neisseria gonorrhoeae. Eur. J. Biochem. 1997, 244, 755-760. (Pubitemid 27130511)
24. Elleby, B.; Chirica, L.C.; Tu, C.; Zeppezauer, M.; Lindskog, S. Characterization of carbonic anhydrase from Neisseria gonorrhoeae. Eur J Biochem. 2001, 268, 1613-9. (Pubitemid 32862694)
25. Adler L.; Brundell J.; Falkbring S.O.; Nyman P.O. Carbonic anhydrase from Neisseria sicca, strain 6021. I. Bacterial growth and purification of the enzyme. Biochim. Biophys. Acta. 1972, 284, 298-310.
26. Sanders, E. Use of sulfonamide carbonic anhydrase inhibitors in treatment of meningococcal carriers: Rationale and report of a clinical trial of ethoxzolamide. Am. J. Med. Sci. 1967, 254, 709-716.
27. MacLeod, M.N.; DeVoe, I.W. Localization of carbonic anhydrase in the cytoplasmic membrane of Neisseria sicca (strain 19). Can J Microbiol. 1981, 27, 87-92. (Pubitemid 11100688)
28. Nafi, B.M.; Miles, R.J.; Butler, L.O.; Carter, N.D.; Kelly, C.; Jeffery, S. Expression of carbonic anhydrase in Neisseriae and other heterotrophic bacteria. J. Med. Microbiol. 1990, 32, 1-7 (Pubitemid 20146223)
29. Vaneechoutte, M.; Verschraegen, G.; Claeys, G.; van den Abeele, A.M. Selective medium for Branhamella catarrhalis with acetazolamide as a specific inhibitor of Neisseria spp. J. Clin. Microbiol. 1988, 26, 2544-2548 (Pubitemid 19001567)
30. Chiricǎ, L.C. ; Petersson, C.; Hurtig, M.; Jonsson, B.H.; Borén, T.; Lindskog, S. Expression and localization of alpha-And beta-carbonic anhydrase in Helicobacter pylori. Biochim Biophys Acta., 2002, 1601, 192-199. (Pubitemid 38224427)
31. Nishimori, I.; Minakuchi, T.; Morimoto, K.; Sano, S.; Onishi, S.; Takeuchi, H.; Vullo, D.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J. Med. Chem. 2006, 49, 2117-2126.
32. Nishimori, I.; Minakuchi, T.; Kohsaki, T.; Onishi, S.; Takeuchi, H.; Vullo, D.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. The β-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 3585-3594. (Pubitemid 46898819)
33. Marcus, E.A.; Moshfegh, A.P.; Sachs, G.; Scott, D.R. The periplasmic alphacarbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol. 2005, 187, 729-738. (Pubitemid 40096259)
34. Shahidzadeh, R.; Opekun, A.; Shiotani, A.; Graham, D.Y. Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: A pilot study. Helicobacter 2005, 10, 136-138. (Pubitemid 40477022)
35. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C.T. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229. (Pubitemid 39004275)
36. Puscas, I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann. N.Y. Acad. Sci. 1984, 429, 587-591. (Pubitemid 14085904)
37. Smith, K.S.; Jakubzick, C.; Whittam, T.S.; Ferry, J.G. Carbonic anhydrase is an ancient enzyme widespread in prokaryotes. Proc. Natl. Acad. Sci. USA. 1999, 96, 15184-15189. (Pubitemid 30019786)
38. Cronk, J.D.; Endrizzi, J.A.; Cronk, M.R.; O'Neill, J.W.; Zhang, K.Y. Crystal structure of E. coli β-carbonic anhydrase, an enzyme with an unusual pHdependent activity. Protein Sci. 2001, 10, 911-922. (Pubitemid 32367481)
39. Cronk, J.D.; Rowlett, R.S.; Zhang, K.Y.; Tu, C.; Endrizzi, J.A.; Lee, J.; Gareiss, P.C.; Preiss, J.R. Identification of a novel noncatalytic bicarbonate binding site in eubacterial β-carbonic anhydrase. Biochemistry 2006, 45, 4351-4361.
40. Suarez Covarrubias, A.; Bergfors, T.; Jones, T.A.; Hogbom, M. Structural mechanics of the pH-dependent activity of the β-carbonic anhydrase from Mycobacterium tuberculosis. J. Biol. Chem. 2006, 281, 4993-4999. (Pubitemid 43847762)
41. Suarez Covarrubias, A.; Larsson, A.M.; Hogbom, M.; Lindberg, J.; Bergfors, T.; Bjorkelid, C.; Mowbray, S.L.; Unge, T.; Jones, T.A. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J. Biol. Chem. 2005, 280, 18782-18789. (Pubitemid 41379579)
42. Vullo, D.; Nishimori, I.; Minakuchi, T.; Scozzafava, A.; Supuran, C.T. Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorg. Med. Chem. Lett. 2011, 21, 3591-3595.
43. 2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J. Mol. Biol. 2009, 385, 1207-1220.
44. Nishimori, I.; Minakuchi, T.; Maresca, A.; Carta, F.; Scozzafava, A.; Supuran, C.T. The β-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. Curr. Pharm. Des., 2010, 16, 3300-3309.
45. Winum, J.Y.; Kohler, S.; Supuran, C.T. Brucella carbonic anhydrases: New targets for designing anti-infective agents. Curr. Pharm. Des. 2010, 16, 3310-3316.
46. Nishimori, I.; Onishi, S.; Takeuchi, H.; Supuran, C.T. The α and β classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr. Pharm. Des. 2008, 14, 622-630 (Pubitemid 351736441)
47. Burghout, P.; Vullo, D.; Scozzafava, A.; Hermans, P.W.M.; Supuran, C.T. Inhibition of the β-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: Towards innovative drug design of antiinfectives ? Bioorg. Med. Chem. 2011, 19, 243-248
48. Joseph, P.; Ouahrani-Bettache, S.; Montero, J.L.; Nishimori, I.; Vullo, D.; Scozzafava, A.; Winum, J.Y.; Köhler, S.; Supuran, C.T. A new Brucella suis β-carbonic anhydrase, bsCA II: Inhibition of bsCA I and II with sulfonamides and sulfamates inhibits the pathogen growth. Bioorg. Med. Chem. 2011, 19, 1172-1178
49. Joseph, P.; Turtaut, F.; Ouahrani-Bettache, S.; Montero, J.L.; Nishimori, I.; Minakuchi, T.; Vullo, D.; Scozzafava, A.; Köhler, S.; Winum, J.Y.; Supuran, C.T. Cloning, characterization and inhibition studies of a β-carbonic anhydrase from Brucella suis. J. Med. Chem. 2010, 53, 2277-2285.
50. Vullo, D.; Nishimori, I.; Scozzafava, A.; Köhler, S.; Winum, J.Y.; Supuran, C.T. Inhibition studies of a β-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides. Bioorg. Med. Chem. Lett. 2010, 20, 2178-2182
51. Nishimori, I.; Minakuchi, T.; Vullo, D.; Scozzafava, A.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors. cloning, characterization, and inhibition studies of a new β-carbonic anhydrase from Mycobacterium tuberculosis. J. Med. Chem. 2009, 52, 3116-3120.
52. Minakuchi, T.; Nishimori, I.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Molecular cloning, characterization and inhibition studies of the Rv1284 β-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. J. Med. Chem. 2009, 52, 2226-2232.
53. Güzel, Ö.; Maresca, A.; Scozzafava, A.; Salman, A.; Balaban, A.T.; Supuran, C.T. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial β-carbonic anhydrases Rv1284 and Rv3273. J. Med. Chem. 2009, 52, 4063-4067.
54. Carta, F.; Maresca, A.; Suarez Covarrubias, A.; Mowbray, S.L.; Jones, T.A.; Supuran, C.T. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active β-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg. Med. Chem. Lett. 2009, 19, 6649-6654.
55. Abuaita B.H.; Withey J.H. Bicarbonate Induces Vibrio cholerae virulence gene expression by enhancing ToxT activity. Infect Immun. 2009, 77, 4111-4120.
56. Kovacikova, G.; Lin, W.; Skorupski, K. The LysR-type virulence activator AphB regulates the expression of genes in Vibrio cholerae in response to low pH and anaerobiosis. J. Bacteriol. 2010, 192, 4181-4191.
57. Rawlings, N.D.; Barrett, A.J. Evolutionary families of peptidases. Biochem. J. 1993, 290, 205-218. (Pubitemid 23081221)
58. Berger, A.; Schechter, I. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos. Trans. R. Soc. Lond. 1970, 257, 249-264.
59. Supuran, C.T.; Winum, J.Y. Introduction to zinc enzymes as drug targets. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran, C.T.; Winum, J.Y. Eds., Wiley, Hoboken, 2009, pp. 3-12.
60. Jung, C.M.; Matsushita, O.; Katayama, S.; Minami, J.; Sakurai, J.; Okabe, A. Identification of metal ligands in the Clostridium histolyticum ColH collagenase. J. Bacteriol. 1999, 181, 2816-2822. (Pubitemid 29211098)
61. Matsushita, O.; Jung, C.M.; Minami, J.; Katayama, S.; Nishi, N.; Okabe, A. A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase. J. Biol. Chem. 1998, 273: 3643-3648. (Pubitemid 28109790)
62. Eckhard, U.; Nüss, D.; Ducka, P.; Schönauer, E.; Brandstetter, H. Crystallization and preliminary X-ray characterization of the catalytic domain of collagenase G from Clostridium histolyticum. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2008, 64, 419-21. (Pubitemid 351631233)
63. Supuran, C.T. Clostridium histolyticum collagenase inhibitors in the drug design. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran, C.T.; Winum, J.Y. Eds., Wiley, Hoboken, 2009, pp. 721 -730.
64. Bond, M.D.; Van Wart, H.E. Purification and separation of individual collagenases of Clostridium histolyticum using red dye ligand chromatography. Biochemistry 1984, 23, 3077-3085.
65. Bond, M.D.; Van Wart, H.E. Characterization of the individual collagenases from Clostridium histolyticum. Biochemistry 1984, 23, 3085-3091.
66. Jung, W.; Winter, H. Considerations for the use of clostridial collagenase in clinical practice. Clin. Drug Invest. 1998, 15, 245-252. (Pubitemid 28163751)
67. Scozzafava, A.; Supuran, C.T. Protease inhibitors: Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties. J. Med. Chem. 2000, 43, 1858-1865. (Pubitemid 30305018)
68. Valee, B.L.; Auld, D.S. Zinc coordination, function and structure of zinc enzymes and other proteins. Biochemistry 1990, 29, 5647-5659. (Pubitemid 20192431)
69. Larsen, K.S.; Zhang, K.; Auld, D.S. D-Phe complexes of zinc and cobalt carboxypeptidase A. J. Inorg. Biochem. 1996, 64, 149-162. (Pubitemid 26357153)
70. Scozzafava, A.; Supuran, C.T. Carbonic anhydrase and matrix metalloproteinase inhibitors. Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of carbonic anhydrase isozymes I, II and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J. Med. Chem. 2000, 43, 3677-3687.
71. Scozzafava, A.; Supuran, C.T. Protease inhibitors. Part 5. Alkyl/arylsulfonyland arylsulfonylureido-/arylureido-glycine hydroxamate inhibitors of Clostridium histolyticum collagenase. Eur. J. Med. Chem. 2000, 35, 299-307. (Pubitemid 30187062)
72. Supuran, C.T.; Briganti, F.; Mincione, G.; Scozzafava, A. Protease inhibitors: Synthesis of L-Alanine hydroxamate sulfonylated derivatives as inhibitors of Clostridium histolyticum collagenase. J. Enzyme Inhib. 2000, 15, 111-128. (Pubitemid 30128983)
73. Supuran, C.T.; Scozzafava, A. Protease inhibitors. Part 7. Inhibition of Clostridium histolyticum collagenase with sulfonylated derivatives of Lvaline hydroxamate. Eur. J. Pharm. Sci. 2000, 10, 67-76. (Pubitemid 30123145)
74. Scozzafava, A.; Supuran, C.T. Protease inhibitors. Part 8. Synthesis of potent Clostridium histolyticum collagenase inhibitors incorporating sulfonylated Lalanine hydroxamate moieties. Bioorg. Med. Chem. 2000, 8, 637-645. (Pubitemid 30122370)
75. Scozzafava, A.; Supuran, C.T. Protease inhibitors. Part 9. Synthesis of Clostridium histolyticum collagenase inhibitors incorporating sulfonyl-Lalanine hydroxamate moieties. Bioorg. Med. Chem. Lett. 2000, 10, 499-502. (Pubitemid 30153622)
76. Scozzafava, A.; Ilies, M.A.; Manole, G.; Supuran, C.T. Protease inhibitors. Part 12. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating sulfonylated N-4-nitrobenzyl-β-Alanine hydroxamate moieties. Eur. J. Pharm. Sci. 2000, 11, 69-79. (Pubitemid 30410846)
77. Clare, B.W.; Scozzafava, A.; Supuran, C.T. Protease inhibitors. Synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type. J. Med. Chem. 2001, 44, 2253-2258. (Pubitemid 32861784)
78. Ilies, M.; Banciu, M.D.; Scozzafava, A.; Ilies, M.A.; Caproiu, M.T.; Supuran, C.T. Protease inhibitors: Synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties. Bioorg. Med. Chem. 2003, 11, 2227-39. (Pubitemid 36457849)
79. Santos, M.A.; Marques, S.; Gil, M.; Tegoni, M.; Scozzafava, A.; Supuran, C.T. Protease inhibitors: Synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties. J. Enzyme Inhib. Med. Chem. 2003, 18, 233-242. (Pubitemid 36827035)
80. Supuran, C.T.; Clare, B.W. Quantum theoretic QSAR of benzene derivatives: Some enzyme inhibitors. J. Enzyme Inhib. Med. Chem. 2004, 19, 237-48. (Pubitemid 39004277)
81. Scozzafava, A.; Supuran, C.T. Protease inhibitors: Synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-Amino-2-mercapto-1,3,4-thiadiazole zinc binding functions. Bioorg. Med. Chem. Lett. 2002, 12, 2667-72. (Pubitemid 35247616)
82. Clinch. T.E.; Hobden, J.A.; Hill, J.M.; O'Callaghan, R.J.; Engel, L.S.; Kaufmann, H.E. Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis. CLAO J. 1992, 18, 245-247.
83. Kuwano, M.; Horibe, Y.; Kawashima, Y. Effect of collagen cross-linking in collagen corneal shields on ocular drug delivery. J. Ocul. Pharmacol. Ther. 1997, 13, 31-40 (Pubitemid 27130720)
84. Harding, K.G.; Bale, S.; Llewellyn, M.; Baggot, J.; Robbins, K. A pilot study of Clostridium collagenase (Collagenase ABC(TM)) ointment in the debridement of dermal ulcers. Clin. Drug Invest. 1996, 11, 139-144. (Pubitemid 26098693)
85. Jung, W.; Winter, H. Considerations for the use of Clostridial collagenase in clinical practice. Clin. Drug Invest. 1998, 15, 245-252. (Pubitemid 28163751)
86. Metzmacher, I.; Ruth, P.; Abel, M.; Friess, W. In vitro binding of matrix metalloproteinase-2 (MMP-2), MMP-9, and bacterial collagenase on collagenous wound dressings. Wound Repair Regen. 2007, 15, 549-55. (Pubitemid 47087648)
87. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717-766. (Pubitemid 30164948)
88. Humeau, Y.; Doussau, F.; Grant, N.J.; Poulain, B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82, 427-446. (Pubitemid 30391899)
89. Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359, 832-834.
90. Schiavo, G.; Rossetto, O.; Catsicas, S.; Polverino de Laureto, P.; DasGupta, B.R.; Benfenati, F.; Montecucco, C. Identification of the nerve terminal targets of botulinum neurotoxins serotypes A, D and E. J. Biol. Chem. 1993, 268, 23784-23787. (Pubitemid 23335346)
91. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898-902. (Pubitemid 28467413)
92. Swaminathan, S.; Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7, 617-9.
93. Arndt, J.W.; Yu, W.; Bi, F.; Stevens, R.C. Crystal structure of botulinum neurotoxin type G light chain: Serotype divergence in substrate recognition. Biochemistry 2005, 44, 9574-80. (Pubitemid 40994351)
94. Arndt, J.W.; Chai, Q.; Christian, T.; Stevens, R.C. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: Repercussions for VAMP-2 substrate specificity. Biochemistry 2006, 45, 3255-62. (Pubitemid 43376344)
95. Hanson, M.A.; Stevens, R.C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution. Nat. Struct. Biol. 2000, 7, 687-92. (Pubitemid 30636682)
96. Agarwal, R.; Eswaramoorthy, S.; Kumaran, D.; Binz, T.; Swaminathan, S. Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212→Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry 2004, 43, 6637-44. (Pubitemid 38697563)
97. Chen, S.; Hall, C.; Barbieri, J.T. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J. Biol. Chem. 2008, 283, 21153-9.
98. Rao, K.N.; Kumaran, D.; Binz, T.; Swaminathan, S. Structural analysis of the catalytic domain of tetanus neurotoxin. Toxicon 2005, 45, 929-39. (Pubitemid 40719795)
99. Martin, L.; Cornille, F.; Coric, P.; Roques, B.P.; Fournié- Zaluski, M.C. β-Amino-thiols inhibit the zinc metallopeptidase activity of tetanus toxin light chain. J. Med. Chem. 1998, 41, 3450-3460. (Pubitemid 28406553)
100. Martin, L.; Cornille, F.; Turcaud, S.; Meudal, H.; Roques, B.P.; Fournié-Zaluski, M.C. Metallopeptidase inhibitors of tetanus toxin: A combinatorial approach. J. Med. Chem. 1999, 49, 515-525. (Pubitemid 29085112)
101. Mastrolorenzo, A.; Supuran, C.T. Botulinum toxin, tetanus toxin and anthrax lethal factor inhibitors. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran, C.T.; Winum, J.Y. Eds., Wiley, Hoboken, 2009, pp. 705 -720.
102. Burnett, J.C.; Schmidt, J.J.; Stafford, R.G., Panchal, R.G., Nguyen, T.L., Hermone, AR., Vennerstrom, J.L., McGrath, C.F., Lane, D.J., Sausville, E.A., Zaharevitz, D.W., Gussio, R., Bavari, S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun. 2003, 310, 84-93. (Pubitemid 37162766)
103. Burnett, J.C., Opsenica, D., Sriraghavan, K., Panchal, R.G., Ruthel, G., Hermone, A.R., Nguyen, T.L., Kenny, T.A., Lane, D.J., McGrath, C.F., Schmidt, J.J., Vennerstrom, J.L., Gussio, R., Solaja, B.A., Bavari, S. A refined pharmacophore identifies potent 4-Amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J. Med. Chem. 2007, 50, 2127-36. (Pubitemid 46683065)
104. Elliott, J.L.; Mogridge, J.; Collier, R.J. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 2000, 39, 6706-6713. (Pubitemid 30354003)
105. Duesbery, N.S., Webb, C.P., Leppla, S.H., Gordon, V.M., Klimpel, K.R., Copeland, T.D., Ahn, N.G., Oskarsson, M.K., Fukasawa, K., Paull, K.D., Vande Woude, G.F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280, 734-737. (Pubitemid 28243347)
106. Vitale, G.; Pellizzari, R.; Recchi, C.; Napolitani, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 1998, 248, 706-711. (Pubitemid 28404486)
107. Pellizzari, R.; Guidi-Rontani, C.; Vitale, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNF-Alpha. FEBS Lett. 1999, 462, 199-204.
108. Menard, A.; Papini, E.; Mock, M.; Montecucco, C. The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors. Biochem. J. 1996, 320, 687-691. (Pubitemid 26417798)
109. Pannifer, A.D.; Wong, T.Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Bienkowska, J.; Lacy, D.B.; Collier, R.J.; Park, S.; Leppla, S.H.; Hanna, P.; Liddington, R.C. Crystal structure of the anthrax lethal factor. Nature 2001, 414, 160-161.
110. Tonello, F.; Naletto, L.; Romanello, V.; Dal Molin, F.; Montecucco, C. Tyrosine-728 and glutamic acid-735 are essential for the metalloproteolytic activity of the lethal factor of Bacillus anthracis. Biochem. Biophys. Res. Commun. 2004, 313, 496-502. (Pubitemid 38021855)
111. De Simone, G.; Menchise, V.; Omaggio, S.; Pedone, C.; Scozzafava, A.; Supuran, C.T. Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: Molecular and X-ray crystallographic studies. Biochemistry, 2003, 42, 9013-9021. (Pubitemid 36935409)
112. Turk, B.E. Discovery and development of anthrax lethal factor metalloproteinase inhibitors. Curr. Pharm. Biotechnol. 2008, 9, 24-33. (Pubitemid 351266967)
113. Gowravaram, M.R., Tomczuk, B.E., Johnson, J.S., Delecki, D., Cook, E.R., Ghose, A.K., Mathiowetz, A.M., Spurlino, J.C., Rubin, B., Smith, D.L.; Pulvino, T.; Wahl, R.C. Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group. J. Med. Chem. 1995, 38, 2570-81.
114. Shoop, W.L., Xiong, Y., Wiltsie, J., Woods, A., Guo, J., Pivnichny, J.V., Felcetto, T., Michael, B.F., Bansal, A., Cummings, R.T., Cunningham, B.R., Friedlander, A.M., Douglas, C.M.; Patel, S.B.; Wisniewski, D.; Scapin, G.; Salowe, S.P.; Zaller, D.M.; Chapman, K.T.; Scolnick, E.M., Schmatz, D.M., Bartizal, K.; MacCoss, M.; Hermes, J.D. Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A. 2005, 102, 7958-63. (Pubitemid 40781045)
115. Xiong, Y, Wiltsie, J, Woods, A, Guo, J, Pivnichny, JV, Tang, W, Bansal, A, Cummings, RT, Cunningham, BR, Friedlander, AM, Douglas, CM, Salowe, SP, Zaller, DM, Scolnick, EM, Schmatz, DM, Bartizal, K, Hermes, JD, MacCoss, M, Chapman, K.T. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg. Med. Chem. Lett. 2006, 16, 964-968. (Pubitemid 43059861)
116. Johnson, S.L., Jung, D., Forino, M., Chen, Y., Satterthwait, A., Rozanov, D.V., Strongin, A.Y., Pellecchia, M. Anthrax lethal factor protease inhibitors: Synthesis, SAR, and structure-based 3D QSAR studies. J. Med. Chem. 2006, 49, 27-30. (Pubitemid 43077317)
117. Min, D.H.; Tang, W.J.; Mrksich, M. Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. Nat. Biotechnol. 2004, 22, 717-23. (Pubitemid 38702828)
118. Soelaiman, S.; Wei, B.Q.; Bergson, P.; Lee, Y.S.; Shen, Y.; Mrksich, M.; Shoichet, B.K.; Tang, W.J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278, 25990-25997. (Pubitemid 36835365)
119. Scott. A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980, 87, 1044-1049. (Pubitemid 10021090)
120. Huang, W.; Foster, J.A.; Rogachefsky, A.S. Pharmacology of botulinum toxin. J. Am. Acad. Dermatol. 2000, 43, 249-259. (Pubitemid 30626002)
121. Solomon, B.A.; Hayman, R. Botulinum toxin type A for palmar and digital hyperhidrosis. J. Am. Acad. Dermatol. 2000, 42, 1026-1029. (Pubitemid 30368673)
122. Eapen, B.R. Molecular biology of botulinum neurotoxin serotype A: A cosmetic perspective. J Cosmet Dermatol. 2008, 7, 221-5.
123. Schulte-Mattler, W.J. Use of botulinum toxin A in adult neurological disorders: Efficacy, tolerability and safety. CNS Drugs 2008, 22, 725-38.
124. Laing, T.A.; Laing, M.E.; O'Sullivan, S.T. Botulinum toxin for treatment of glandular hypersecretory disorders. J Plast. Reconstr. Aesthet. Surg. 2008, 61, 1024-8.
125. Jabbari, B. Botulinum neurotoxins in the treatment of refractory pain. Nat. Clin. Pract. Neurol. 2008, 4, 676-85.
126. Eccleston, K.J.; Woolley, P.D. Botulinum toxin for urogenital conditions. Int J STD AIDS. 2008, 19, 797-9.
127. De Ridder, D. Botulinum toxin: Future developments. BJU Int. 2008, 102 Suppl 1, 20-22.
128. Supuran, C.T. Bacterial zinc proteases as orphan targets. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran, C.T.; Winum, J.Y. Eds., Wiley, Hoboken, 2009, pp. 675 -704.
129. Supuran, C.T. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med. Chem. 2011, 3, 1165-1180.